Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations

INTRODUCTION: Dacomitinib and gefitinib are irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and EGFR-activating mutations. Pharmacokinetic (PK) studies in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jerry, Nickens, Dana, Wilner, Keith, Tan, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593125/
https://www.ncbi.nlm.nih.gov/pubmed/34120312
http://dx.doi.org/10.1007/s40487-021-00156-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593125/
https://www.ncbi.nlm.nih.gov/pubmed/34120312
http://dx.doi.org/10.1007/s40487-021-00156-2

Ejemplares similares